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Previewscompounds target the stem cell popula-
tion effectively. This is important because
these cells are thought to be the source of
the residual disease that remains even
after long-term drug treatment.
If it lives up to its promise, DCC-2036
will play a role in the CML and AML
stories. Regardless of its final contribution
to the clinical management of these
diseases, switch control drugs are
certainly a very elegant solution to the
BCR-ABLT315I problem.
REFERENCES
Chan, W.W., Wise, S.C., Kaufman, M.D., Ahn,
Y.M., Ensinger, C.L., Haack, T., Hood, M.M.,Jones, J., Lord, J.W., Lu,W.P., et al. (2011). Cancer
Cell 19, this issue, 556–568.
Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin,
H., Arlinghaus, R., and Talpaz, M. (2003). Blood
101, 690–698.
Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta,
D.J., Reese, S.F., Ford, J.M., Capdeville, R., and
Talpaz, M. (2001). N. Engl. J. Med. 344, 1038–
1042.
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N.,
Paquette, R., Rao, P.N., and Sawyers, C.L. (2001).
Science 293, 876–880.
O’Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A.,
Rivera, V.M., Wang, F., Adrian, L.T., Zhou, T.,
Huang, W.S., Xu, Q., et al. (2009). Cancer Cell 16,
401–412.Cancer CelShah, N.P., Skaggs, B.J., Branford, S., Hughes,
T.P., Nicoll, J.M., Paquette, R.L., and Sawyers,
C.L. (2007). J. Clin. Invest. 117, 2562–2569.
Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D.,
and Sawyers, C.L. (2004). Science 305, 399–401.
Weisberg, E., Manley, P.W., Cowan-Jacob, S.W.,
Hochhaus, A., and Griffin, J.D. (2007). Nat. Rev.
Cancer 7, 345–356.
Weisberg, E., Choi, H.G., Ray, A., Barrett, R.,
Zhang, J., Sim, T., Zhou, W., Seeliger, M.,
Cameron, M., Azam, M., et al. (2010). Blood 115,
4206–4216.
Zhang, J., Adria´n, F.J., Jahnke, W., Cowan-Jacob,
S.W., Li, A.G., Iacob, R.E., Sim, T., Powers, J.,
Dierks, C., Sun, F., et al. (2010). Nature 463,
501–506.Resisting Targeted Therapy:
Fifty Ways to Leave Your EGFRPaul Workman1,* and Paul A. Clarke1
1Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics,
The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton SM2 5NG, UK
*Correspondence: Paul.workman@icr.ac.uk
DOI 10.1016/j.ccr.2011.03.020
Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance
is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by
which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic
workarounds.Paul Simon famously sang about the fifty
ways to leave your lover. Two recent
studies by Sequist et al. (2011) and Bivona
et al. (2011) have revealed several addi-
tional new ways by which non-small cell
lung cancers (NSCLC) can escape the
clutches of small molecule inhibitors of
the epidermal growth factor receptor
(EGFR) tyrosine kinase. Whether there
will turn out to be fifty, or even more
mechanisms through which resistance
can be mediated—either de novo or
acquired during treatment—remains to
be seen. What is clear is that there are
a growing number of ingenious molecular
means by which cancers can circumvent
inhibitors of EGFR and other oncogenic
kinases. Although representing thera-
peutic challenges to the clinician, thesemechanisms also suggest rational new
therapeutic opportunities to improve clin-
ical outcomes. Furthermore, by using
kinase inhibitors as chemical probes
(Workman and Collins, 2010) to interro-
gate human cancers, we are gaining
considerable fundamental as well as
translational insights into the diverse
mechanisms of human oncogenesis.
The extraordinary success of imatinib in
prolonging the lives of patients with
chronic myeloid leukemia (CML) through
the inhibition of the pathogenic tyrosine
kinase activity of BCR-ABL has had
a major scientific impact in validating the
concept of single kinase addiction in the
clinic (Druker et al., 2006). Furthermore,
the principle of treating such oncogene
addiction (Weinstein, 2002) with inhibitorsof the respective major driver kinases has
proved to be applicable to many other
types of cancer. On the other hand, the
tumor regression and prolonged survival
obtained are commonly not as sustained
as in CML (Sawyers, 2009).




chemotherapy has limited effectiveness.
Approximately 10% of NSCLCs in
western populations harbor somatic
mutations in exons encoding the tyrosine
kinase domain of EGFR, and these occur
with an increased frequency in adenocar-
cinomas arising in nonsmokers, females,
and individuals of Asian ethnicity. These
mutations cause activated signalingl 19, April 12, 2011 ª2011 Elsevier Inc. 437
Figure 1. Ways to leave your EGFR inhibitor: Biochemical pathways leading to resistance to small molecule EGFRdrugs such as gefitinib and
erlotinib
(A) Structures of two approved EGFR TKIs, gefitinib and erlotinib, used in the treatment of NSCLC.
(B) Ribbon diagram of wild-type human EGFR (PDB code 2ITY), illustrating binding of gefitinib to the active site of the kinase. The magenta ball-stick (located just
above the gefitinib molecule in the active site) indicates the gatekeeper residue (threonine790) that is commonly mutated to methionine (T790M), resulting in
reduced inhibitor binding and drug resistance.
(C) Simplified pathway diagram of EGFR signaling through RAS/MEK/ERK and PI3K/PDK1/AKT indicating the points of mutation/amplification in EGFR TKI resis-
tance as reported by Sequist and colleagues. The resistance mechanisms include the EGFR T790M gatekeeper mutation, amplification of EGFR T790M, MET
amplification, and PI3KCAmutation (note that additional epithelial to mesenchymal transition changes and transformation from the NSCLC to the SCLC pheno-
type also lead to resistance but are not covered by this illustration). The illustration also shows the FAS/NF-kB signaling arm downstream of the FAS death
receptor that was shown to be important in TKI resistance by Bivona and colleagues.
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Previewsdownstream of the receptor and
commonly result in dramatic responses
to the selective reversible tyrosine kinase
inhibitors (TKIs) gefitinib and erlotinib
(Figure 1A), thus defining a subset of
NSCLC characterized by addiction to the
activated EGFR pathway (Haber et al.,
2005). Despite around 70% of EGFR438 Cancer Cell 19, April 12, 2011 ª2011 Elsmutant NSCLC patients experiencing
significant and durable tumor regressions
with EGFR TKIs, 30% fail to respond, and
the vast majority of responders develop
acquired resistance (Mok et al., 2009;
Rosell et al., 2009; Jackman et al., 2010).
Roughly half the mutant EGFR NSCLC
cases with acquired resistance to TKIsevier Inc.have a secondary ‘‘gatekeeper’’ mutation
in EGFR (T790M) (Figure 1B) that reduces
drug binding to the kinase target, while
a further 15%–20% have amplifications in
theMET receptorgene,providingabypass
signaling pathway through kinase switch-
ing or via receptor heterodimerization
(see references in Sequist et al., 2011).
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PreviewsIn the first of the two new papers, Se-
quist et al. (2011) obtained tumor biopsies
before and after treatment from 37 EGFR
mutant NSCLC patients who were initially
responsive to TKIs. Tumor DNA was
profiled to detect mutations in 13 key
cancer genes. The now familiar gate-
keeper mutation in EGFR (49% of cases)
and amplification of MET (5%) were
confirmed (Figure 1C). Important new
findings were that clinical resistance was
also associated with amplification of the
EGFR T790M resistant allele (8%) and
mutation of PIK3CA that encodes the
p110a catalytic subunit of PI3 kinase
(5%), the latter being consistent with
laboratory studies in which introduction
of PIK3CA into NSCLC cells induced TKI
resistance. Activated PI3 kinase likely
operates independently downstream of
EGFR (Figure 1C).
Interestingly, Sequist et al. (2011)
observed several additional (5%) cases
in which TKI resistance developed by
cells undergoing a transition from the
epithelial to the more aggressive mesen-
chymal phenotype—also seen in labora-
tory studies and detected here by routine
pathology and biomarker expression.
Surprisingly, in 14% of patients, TKI resis-
tance was associated with transformation
from NSCLC into the phenotype of small
cell lung cancers (SCLC), which then
duly responded in four out of five cases
to standard treatments for that disease.
Sequist et al. (2011) also obtained
multiple longitudinal samples in three
TKI-resistant NSCLC patients. In two
patients, responses were seen after
reintroducing TKI treatment following
a drug-free interval after resistance devel-
oped, and these responses were concur-
rent with a loss of detectability of the
T790M resistance mutation. In the third
patient, TKI resistance was associated
with emergence of the SCLC phenotype
(together with a PIK3CA mutation),
leading to successful implementation of
SCLC-based chemo-radiation therapy;
subsequent reappearance of adenocarci-
noma lacking both neuroendocrine
markers and the PIK3CA mutation led
to successful readministration of TKI
therapy, after which TKI-resistant disease
with SCLC phenotype and PIK3CA
mutation once again reemerged. Though
anecdotal, these results support other
findings (discussed by Sequist et al.,
2011), indicating that resistance mecha-nisms are lost without the continued
selective pressure of TKI therapy.
In the other new paper, Bivona et al.
(2011) took a different approach. They
screened 2000 ‘‘cancer relevant genes’’
using short hairpin RNAs to identify
genes that, when silenced, would specif-
ically sensitize the NSCLC cell line
H1650, which is resistant to TKI treat-
ment despite having a mutation associ-
ated with sensitivity to TKIs and lacking
known clinical resistance mechanisms.
Of the 36 screen hits, 18 genes, including
FAS/CD95, were involved directly or indi-
rectly with NF-kB signaling. Since FAS
death receptor and NF-kB signaling are
involved in cell survival and can promote
tumor growth, Bivona et al. (2011)
focused on these. Following thorough
validation of hits in additional models,
they showed that knockdown of the
RELA subunit of NF-kB and of the func-
tionally related c-FLIP or RIPK also
increased sensitivity to EGFR TKI
therapy but not to cytotoxic agents in
the TKI-resistant cells. Further biochem-
ical data supported the view that persis-
tent NF-kB signaling was implicated in
resistance to TKI-induced apoptosis,
and the results were extended to tumor
xenograft models, in which silencing of
FAS and RELA increased the response
of H1650 cancers in vivo to EGFR TKI
treatment.
Since IkB kinase (IKKb or IKBKB)
decreases IkB stability leading to NF-kB
activation, NF-kB pathway blockade can
be achieved by inhibition of IKKb. Consis-
tent with this, Bivona et al. (2011) showed
that sensitization to TKI treatment in resis-
tant NSCLC models could be obtained
using a small molecule IKKb inhibitor
in vitro and with IKKb knockdown in tumor
xenografts.
Demonstrating the clinical relevance of
the findings, Bivona et al. (2011) went on
to show that low expression of the
NF-kB inhibitory protein IkB, indicative
of a ‘‘high NF-kB activation state,’’ was
predictive of a poorer clinical outcome in
a cohort of erlotinib-treated EGFR mutant
NSCLC patients lacking evidence of the
T790M gatekeeper mutation. In another
cohort, IkB expression did not predict
outcome from surgery and chemo-
therapy, indicating specificity. Thus, the
results suggest that combining an NF-kB
pathway inhibitor with EGFR inhibitors
may be therapeutically advantageous.Cancer CelThe results obtained in these two
important studies are consistent with an
emerging overall model in which resis-
tance can develop at the genetic level,
owing to Darwinian clonal selection—in
which the drug treatment represents an
additional selective pressure—as well as
at the biochemical level, involving feed-
back loops in the pathway or network
and reversible epigenetic mechanisms.
Overall, the new results stress the
importance of understanding the multiple
molecular mechanisms of de novo and
acquired resistance to TKIs in NSCLC
and of modifying the therapy accordingly,
including use of single drugs or more
likely combinatorial treatments that are
designed to overcome resistance. Thera-
peutic opportunities for EGFR-addicted
NSCLC that are indicated by the two
recent studies include the use of existing
or novel EGFR TKIs, together with inhibi-
tors of MET, the PI3 kinase pathway, and
IKKb plus SCLC cytotoxic agents. If
confirmed in larger prospective studies,
the results would reinforce the ongoing
selection of treatment options informed
by repeated tumor profiling in order to
reverse or avoid drug resistance. Clearly,
the development of less invasivemultiplex
profiling methods, such as analysis of
circulating tumor cells and plasma DNA
sequencing, and perhaps in the future
proteomic and metabolomic analysis,
would help with this, especially if there
turn out to be fifty ways to escape from
EGFR therapy.ACKNOWLEDGMENTS
We thank Drs. Bissan Al-Lazikani and John
Caldwell for help with Figure 1.REFERENCES
Bivona, T.G., Hieronymus, H., Parker, J., Chang,
K., Taron, M., Rosell, R., Moonsamy, P., Dahlman,
K., Miller, V.A., Costa, C., et al. (2011). Nature 471,
523–526.
Druker, B.J., Guilhot, F., O’Brien, S.G., Gathmann,
I., Kantarjian, H., Gattermann, N., Deininger, M.W.,
Silver, R.T., Goldman, J.M., Stone, R.M., et al.
(2006). N. Engl. J. Med. 355, 2408–2417.
Haber, D.A., Bell, D.W., Sordella, R., Kwak, E.L.,
Godin-Heymann, N., Sharma, S.V., Lynch, T.J.,
and Settleman, J. (2005). Cold Spring Harb.
Symp. Quant. Biol. 70, 419–426.
Jackman, D., Pao, W., Riely, G.J., Engelman, J.A.,
Kris, M.G., Ja¨nne, P.A., Lynch, T., Johnson, B.E.,
and Miller, V.A. (2010). J. Clin. Oncol. 28, 357–360.l 19, April 12, 2011 ª2011 Elsevier Inc. 439
Cancer Cell
PreviewsMok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H.,
Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B.,
Margono, B., Ichinose, Y., et al. (2009). N. Eng. J.
Med. 361, 947–957.
Rosell, R., Moran, T., Queralt, C., Porta, R., Carde-
nal, F., Camps, C., Majem, M., Lopez-Vivanco, G.,440 Cancer Cell 19, April 12, 2011 ª2011 ElsIsla, D., Provencio, M., et al; Spanish Lung Cancer
Group. (2009). N. Eng. J. Med. 361, 958–967.
Sawyers, C.L. (2009). Nat. Med. 15, 1158–1161.
Sequist, L.V., Waltman, B.A., Dias-Santagata, D.,
Digumarthy, S., Turke, A.B., Fidias, P., Bergethon,evier Inc.K., Shaw, A.T., Gettinger, S., Cosper, A.K., et al.
(2011). Sci. Transl. Med. 3, 75.
Weinstein, I.B. (2002). Science 297, 63–64.
Workman, P., and Collins, I. (2010). Chem. Biol. 17,
561–577.
